ArticleHeliyon2025
Green extraction cascade of UV-absorbing compounds, alginate, and fucoidan from
Article in Heliyon, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of this study was to evaluate Caribbean Mexican seaweed as a raw material for the production of fucoidans, alginates, and bioactive extracts with antioxidant activity, total flavonoid content, total phenolic content, and UV absorbance. Extractions were first performed using varying ethanol concentrations and maceration times, with the optimal treatment selected based on its superior antioxidant activity, flavonoid and phenolic contents, and UV absorbance. The solid fraction from this treatment was then subjected to extraction using green solvents, specifically natural deep eutectic solvents (NADESs) and ultrasound-assisted extraction (UAE), to isolate alginate and fucoidan. The green extraction cascade enables the recovery of multiple value-added products from each fraction, showcasing both versatility and sustainability. The new DES combination yielded a high amount of crude fucoidan (0.4103 ± 0.0042 g g⁻
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.